On August 13, 2024, Otsuka Precision Health and Click Therapeutics announced the commercial launch of Rejoyn, the first FDA-cleared prescription digital therapeutic for major depressive disorder (MDD). Approved in March 2024, Rejoyn is designed as an adjunct to traditional outpatient care for adults with MDD who are already on antidepressant medication. The digital therapeutic uses cognitive and emotional brain training exercises, including the emotional faces memory task and cognitive behavioral therapy techniques, to target and modify neural connections associated with depression. This six-week program aims to alleviate symptoms and improve patient outcomes through a non-invasive, accessible platform.
Rejoyn can be prescribed through virtual consultations via Wheel Health, Inc., with BlinkRx serving as the exclusive pharmacy provider. The digital therapy is available for $50 during an introductory period, with a standard price of $200 for payors. The treatment has shown promising results in clinical trials, with participants demonstrating significant improvements in depression symptoms. This innovative approach offers a new tool for healthcare providers and patients seeking alternatives to traditional therapies, with no reported side effects related to Rejoyn.
